Infections are a major cause of morbidity and mortality in kidney transplant recipients. Due to the prevalence of HCV infection in the general population in the Middle East, especially Egypt, sometimes transplanting patients who are HCV positive or from donors who are positive is unavoidable.
The introduction of anti-HCV medication and pre-transplant screening, immunization, and post-transplant prophylactic antimicrobials has helped reduce that risk. However, because transplant recipients may not manifest typical signs and symptoms of infection, diagnoses may be confounded.
Furthermore, treatment regimens may be complicated by drug interactions and the need to maintain immunosuppression to avoid allograft rejection. Transplantation of a kidney from a hepatitis C virus (HCV)-infected kidney donor may cause HCV infection in the recipient.
Presentation: HCV infection in kidney transplant, Niraj Manubhai Desai, USA
Live Q&A with Niraj Manubhai Desai, USA
Presentation: HCV treatment in liver transplant, Mohamed Hani Hafez, Egypt
Live Q&A with Mohamed Hani Hafez, Egypt
Masterclass closig remarks